Skip to content
Business
Link copied to clipboard
Link copied to clipboard

Philly gene therapy firm based on Temple University research raises $11 million

The company is working on treatments for genetically-based cardiovascular diseases.

The newly named Lewis Katz School of Medicine on North Broad Street has about 1,000 medical and doctoral students enrolled. The building originally opened in 2009.
The newly named Lewis Katz School of Medicine on North Broad Street has about 1,000 medical and doctoral students enrolled. The building originally opened in 2009.Read moreALEJANDRO A. ALVAREZ / Staff Photographer

Renovacor Inc., a Philadelphia-based gene therapy company based on research by a professor at Temple University’s Lewis Katz School of Medicine, received $11 million in first-round venture capital funding.

The money will be used to prepare for human clinical trials.

The research by Arthur Feldman, the Temple professor, is aimed at treating a version of a heart disease called dilated cardiomyopathy that is caused by a mutated gene. Dilated cardiomyopathy is a condition involving the weakening of the heart’s main pumping chamber.

Novartis Venture Fund, Broadview Ventures, and BioAdvance led the investment. They were joined by New Leaf Venture Partners and Innogest Capital.

Development work for Renovacor, which employs at least five people, is done at Feldman’s lab. Philadelphia-based Magdalene Cook is the company’s chief executive.